Biomedical papers, 2018 (vol. 162), issue 1

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018, 162(1):18-25 | 10.5507/bp.2018.007

Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice

Leos Landaa,b, Jan Juricaa,c, Jiri Slivad, Monika Pechackovae, Regina Demlovaa,c
a Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
b Department of Applied Pharmacy, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic
c Masaryk Memorial Cancer Institute, Brno, Czech Republic
e Hospital Pharmacy, St. Anne's University Hospital, Brno, Czech Republic
d Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

The use of cannabis for medical purposes has been recently legalised in many countries including the Czech Republic. As a result, there is increased interest on the part of physicians and patients in many aspects of its application. This mini review briefly covers the main active substances of the cannabis plant and mechanisms of action. It focuses on two conditions, cancer pain and spasticity in multiple sclerosis, where its effects are well-documented. A comprehensive overview of a few cannabis-based products and the basic pharmacokinetics of marijuana's constituents follows. The review concludes with an outline for preparing cannabis (dried inflorescence) containing drug dosage forms that can be produced in a hospital pharmacy.

Keywords: cannabis, pain, cancer, spasms, multiple sclerosis, mechanism of action, THC, cannabinoids

Received: October 10, 2017; Accepted: February 26, 2018; Prepublished online: March 19, 2018; Published: March 27, 2018


References

  1. Hanus LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 2009;29(2):213-71. Go to original source... Go to PubMed...
  2. Laursen L. Botany: The cultivation of weed. Nature 2015;525(7570):S4-S5. Go to original source... Go to PubMed...
  3. Turner CE, ElSohly MA, Boeren EG. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 1980;43(2):169-234. Go to original source... Go to PubMed...
  4. Pagani A, Scala F, Chianese G, Grassi G, Appendino G, Taglialatela-Scafati O. Cannabioxepane, a novel tetracyclic cannabinoid from hemp, Cannabis sativa L. Tetrahedron 2011;19(67):3369-73. Go to original source...
  5. Long T, Wagner M, Demske D, Leipe C, Tarasov PE. Cannabis in Eurasia: origin of human use and Bronze Age trans-continental connections. Vegetation History and Archaeobotany 2017;26(2):245-58. Go to original source...
  6. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006;28(2):153-7. Go to original source... Go to PubMed...
  7. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag 2009;5(3):153-68. Go to original source... Go to PubMed...
  8. Gorji A, Khaleghi GM. History of headache in medieval Persian medicine. Lancet Neurol 2002;1(8):510-5. Go to original source... Go to PubMed...
  9. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag 2001;6(2):80-91. Go to original source... Go to PubMed...
  10. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di M, V, Jutras-Aswad D, Notcutt WG, Martinez-Org, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014;55(6):791-802. Go to original source... Go to PubMed...
  11. Hanus L, Meyer S, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: A Unified Critical Inventory. Natural Products Reports 2016;12(33):1357-92. Go to original source...
  12. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78(5):539-48. Go to original source... Go to PubMed...
  13. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003;2(5):291-8. Go to original source... Go to PubMed...
  14. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011;163(7):1344-64. Go to original source... Go to PubMed...
  15. Levine J. Origin of cannabinol. J Am Chem Soc 1944;66(11):1868-70. Go to original source...
  16. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86(8):1646-7. Go to original source...
  17. Santavý F. Notes on the structure of cannabidiol compounds. Acta Universitatis Palackianae Olomucensis (Olomouc), Facultatis Medicae 1964;35:5-9.
  18. Mechoulam R, Shvo Y. The structure of cannabidiol. Tetrahedron 1963;19:2073-8. Go to original source... Go to PubMed...
  19. Maione S, Costa B, Di M, V. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain 2013;154 Suppl 1(S87-S93). Go to original source... Go to PubMed...
  20. Krejci Z, Santavy F. Isolace dalších látek z listí indického konopí Cannabis sativa L. Acta Universitatis Palackianae Olomucensis (Olomouc), Facultatis Medicae 1955;6:59-66.
  21. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47. Go to original source... Go to PubMed...
  22. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J 2013;280(9):1918-43. Go to original source... Go to PubMed...
  23. Kruk-Slomka M, Dzik A, Budzynska B, Biala G. Endocannabinoid System: the Direct and Indirect Involvement in the Memory and Learning Processes-a Short Review. Mol Neurobiol 2017; 54(10):8332-47. Go to original source... Go to PubMed...
  24. Abdel-Salam OM, Salem NA, El-Sayed El-Shamarka M, Al-Said AN, Seid HJ, El-Khyat ZA. Cannabis-induced impairment of learning and memory: effect of different nootropic drugs. EXCLI J 2013;12:193-214. Go to PubMed...
  25. Grotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids. Cannabinoids 2017;1(1):10-4.
  26. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74(2):129-80. Go to original source... Go to PubMed...
  27. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le FG, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232(1):54-61. Go to original source... Go to PubMed...
  28. Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 2003;285(3):G566-G576. Go to original source... Go to PubMed...
  29. Ross RA. Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 2003;140(5):790-801. Go to original source... Go to PubMed...
  30. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Broer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M. The Concise Guide to PHARMACOLOGY 2013/14: overview. Br.J Pharmacol 2013;170(8):1449-58.
  31. Zubrzycki M, Liebold A, Janecka A, Zubrzycka M. A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol 2014;65(2):171-81. Go to PubMed...
  32. Brown KJ, Laun AS, Song ZH. Cannabidiol, a novel inverse agonist for GPR12. Biochem Biophys Res Commun 2017;493(1):451-4. Go to original source... Go to PubMed...
  33. Braun IM, Meyer FL, Gagne JJ, Nabati L, Yuppa DP, Carmona MA, Burstein HJ, Suzuki J, Nayak MM, Martins Y. Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology 2017; 26(8):1087-92. Go to original source... Go to PubMed...
  34. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, Egawa T, Kitamura Y, Uchida N, Nishimura R, Egashira N, Iwasaki K, Fujiwara M. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 2008;1188:157-64. Go to original source... Go to PubMed...
  35. Bisogno T, Hanus L, De PL, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di M, V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845-52. Go to original source... Go to PubMed...
  36. Landa L, Sulcova A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Vet Med-Czech 2016;61(3):111-22. Go to original source...
  37. Rock EM, Parker LA. Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. Front Pharmacol 2016;7:221. Go to PubMed...
  38. Nightingale SL. Dronabinol approved for use in anorexia associated with weight loss in patients with AIDS. JAMA 1993;269(11):1361. Go to original source... Go to PubMed...
  39. Milstein SL, MacCannell K, Karr G, Clark S. Marijuana-produced changes in pain tolerance. Experienced and non-experienced subjects. Int Pharmacopsychiatry 1975;10(3):177-82. Go to original source... Go to PubMed...
  40. Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107(5):785-96. Go to original source... Go to PubMed...
  41. Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology 2013;38(10):1984-92. Go to original source... Go to PubMed...
  42. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000;59(3):261-75. Go to original source... Go to PubMed...
  43. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323(7303):13-6. Go to original source... Go to PubMed...
  44. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68(7):515-21. Go to original source... Go to PubMed...
  45. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34(3):672-80. Go to original source... Go to PubMed...
  46. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9(6):506-21. Go to original source... Go to PubMed...
  47. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182(14):E694-E701. Go to original source... Go to PubMed...
  48. NICE. Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings. NICE Clinical Guidelines 2013.
  49. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003;102(1-2):211-6. Go to original source... Go to PubMed...
  50. Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician 2014;60(12):1083-90. Go to PubMed...
  51. Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA 2015;313(24):2474-83. Go to original source... Go to PubMed...
  52. Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. Can Fam Physician 2015;61(8):e372-e381. Go to PubMed...
  53. Ware MA, Wang T, Shapiro S, Collet JP. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain 2015;16(12):1233-42. Go to original source... Go to PubMed...
  54. Kramer JL. Medical marijuana for cancer. CA Cancer J Clin 2015;65(2):109-22. Go to original source... Go to PubMed...
  55. Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55(3):324-8. Go to original source... Go to PubMed...
  56. Schon F, Hart PE, Hodgson TL, Pambakian AL, Ruprah M, Williamson EM, Kennard C. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 1999;53(9):2209-10. Go to original source... Go to PubMed...
  57. Page SA, Verhoef MJ, Stebbins RA, Metz LM, Levy JC. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 2003;30(3):201-5. Go to original source... Go to PubMed...
  58. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62(11):2098-2100. Go to original source... Go to PubMed...
  59. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62(7):1105-9. Go to original source... Go to PubMed...
  60. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10(4):417-24. Go to original source... Go to PubMed...
  61. Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83(11):1125-32. Go to original source... Go to PubMed...
  62. Chiurchiù V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog Neurobiol 2018;160:82-100. Go to original source... Go to PubMed...
  63. Medical uses of cannabinoids. https://www.dynamed.com/topics/dmp~AN~T901291/Medical-uses-of-cannabinoids 2017.
  64. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4(8):1770-804. Go to original source... Go to PubMed...
  65. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168):657-90.
  66. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ. Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. J Anal Toxicol 2017;41(2):83-99. Go to original source... Go to PubMed...
  67. Hudak M, Severn D, Nordstrom K. Edible Cannabis-Induced Psychosis: Intoxication and Beyond. Am J Psychiatry 2015;172(9):911-2. Go to original source... Go to PubMed...
  68. Favrat B, Menetrey A, Augsburger M, Rothuizen LE, Appenzeller M, Buclin T, Pin M, Mangin P, Giroud C. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry 2005;5:17. Go to original source... Go to PubMed...
  69. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry 2012;7(4):149-56. Go to PubMed...
  70. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009;55(12):2180-9. Go to original source... Go to PubMed...
  71. SmPC. Sativex. 2017.
  72. Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69(5):1135-47. Go to original source... Go to PubMed...
  73. Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Rikkert MG, Kramers C. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol 2014;24(9):1475-82. Go to original source... Go to PubMed...
  74. Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM. Novel Delta(9) -tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects. Br.J Clin Pharmacol 2012;74(1):42-53. Go to original source... Go to PubMed...
  75. Heuberger JA, Guan Z, Oyetayo OO, Klumpers L, Morrison PD, Beumer TL, van Gerven JM, Cohen AF, Freijer J. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clin Pharmacokinet 2015;54(2):209-19. Go to original source... Go to PubMed...
  76. Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O. Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. J Pharmacol Toxicol Methods 2017;85:49-54. Go to original source... Go to PubMed...
  77. Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Rikkert MG, Kramers C. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol 2014;24(9):1475-82. Go to original source... Go to PubMed...
  78. Johansson E, Agurell S, Hollister LE, Halldin MM. Prolonged apparent half-life of delta 1-tetrahydrocannabinol in plasma of chronic marijuana users. J Pharm Pharmacol 1988;40(5):374-5. Go to original source... Go to PubMed...
  79. van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, Rikkert MG. Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev 2014;14:56-64. Go to original source... Go to PubMed...
  80. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996;34(10):446-52. Go to PubMed...
  81. Zendulka O, Dovrtělová G, Nosková K, Turjap M, Šulcová A, Hanuš L, Juřica J. Cannabinoids and Cytochrome P450 Interactions. Curr Drug Metab 2016;17(3):206-26. Go to original source... Go to PubMed...
  82. Perrotin-Brunel H, Buijs W, van Spronsen J, van Roosmalen M, Peters C, Verpoorte R, Witkamp G. Decarboxylation of Delta(9)-tetrahydrocannabinol: Kinetics and molecular modeling. Journal of Molecular Structure 2011;987(1-3):67-73. Go to original source...
  83. Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal 2016;128:201-9. Go to original source... Go to PubMed...
  84. Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Munoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 2015;12(1):185-99. Go to original source... Go to PubMed...